Table III.
Association of immunostaining with initial and second cancer in the HT group.
| Clincopathological criteria | Initial cancer | Second cancer | P-value |
|---|---|---|---|
| PgR status | |||
| Positive | 39 | 36 | 0.432 |
| Negative | 2 | 5 | |
| HER2 status | |||
| Positive | 6 | 6 | 1.000 |
| Negative | 35 | 35 | |
| Ki67 status | |||
| <14% | 35 | 25 | 0.004 |
| ≥14% | 4 | 16 | |
| N/A | 2 | 0 | |
| Subtype | |||
| Luminal A | 28 | 20 | – |
| Luminal B | 5 | 15 | |
| HER2 enriched | 6 | 6 | |
| N/A | 2 | 0 | |
| pS6 status | |||
| Positive | 6 | 9 | 0.570 |
| Negative | 33 | 32 | |
| N/A | 2 | ||
| pMAPK status | |||
| Positive | 11 | 10 | 0.801 |
| Negative | 28 | 31 | |
| N/A | 2 | ||
HT group, patients who received hormone therapy for the initial cancer; PgR, progesterone-receptor; HER2, human epidermal growth factor receptor 2; pS6, phospho-S6 ribosomal protein; pMAPK, phospho-mitogen-activated protein kinase; Ki67, proliferation marker protein Ki67; N/A, not available.